Effectiveness and Tolerability of the On-demand Use of Combined Dapoxetine With Tadalafil and Combined Dapoxetine With Lidocaine 5% Spray in Treatment of Patients With Lifelong Premature Ejaculation and Non-responding to Dapoxetine Alone.

Last updated: January 8, 2021
Sponsor: Sohag University
Overall Status: Active - Recruiting

Phase

3

Condition

Premature Ejaculation

Treatment

N/A

Clinical Study ID

NCT04703127
3/2020
  • Ages 20-50
  • Male

Study Summary

Therefore, this study will aim to assess the effectiveness and tolerability of the on-demand use of combined dapoxetine with tadalafil and combined dapoxetine with lidocaine 5% spray in treatment of patients with lifelong premature ejaculation and non-responding to dapoxetine alone.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • lifelong premature ejaculation and non-responding to dapoxetine alone.

Exclusion

Exclusion Criteria:

  • diabetes mellitus,
  • chronic prostatitis,
  • Advanced renal or hepatic diseases
  • neurological diseases
  • C.N.S. medications

Study Design

Total Participants: 60
Study Start date:
March 30, 2020
Estimated Completion Date:
January 30, 2021

Study Description

This study will be carried out on 60 patients with lifelong premature ejaculation and non-responding to dapoxetine alone.

All patients will be equally divided into 2 groups (30 patients each). Group 1 was given on-demand 30 mg dapoxetine and 10 mg tadalafil 1 h before intercourse. Group 1 was given on-demand 30 mg dapoxetine 1 h before intercourse and apply lidocaine 5% spray on the glans penis 10 minutes the wash before intercourse.

Connect with a study center

  • Mohammed Abu El-Hamd

    Sohag, 82524
    Egypt

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.